RhumbLine Advisers’s Takeda Pharmaceutical TAK Stock Holding History

RhumbLine Advisers’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.95M	Sell	121,426 -235	-0.2%	-$3.89K	﹤0.01%	1950
2026 Q1	$2.25M	Buy	121,661 +4,025	+3%	+$70.6K	﹤0.01%	1782
2025 Q4	$1.83M	Buy	117,636 +57,456	+95%	+$821K	﹤0.01%	1916
2025 Q3	$881K	Sell	60,180 -7,720	-11%	-$115K	﹤0.01%	2317
2025 Q2	$1.05M	Sell	67,900 -2,732	-4%	-$40.4K	﹤0.01%	2218
2025 Q1	$1.05M	Sell	70,632 -3,905	-5%	-$54.7K	﹤0.01%	2150
2024 Q4	$987K	Buy	74,537 +188	+0.3%	+$2.58K	﹤0.01%	2255
2024 Q3	$1.06M	Hold	74,349	–	–	﹤0.01%	2240
2024 Q2	$962K	Buy	74,349 +6,303	+9%	+$83.4K	﹤0.01%	2268
2024 Q1	$945K	Buy	68,046 +10,420	+18%	+$152K	﹤0.01%	2283
2023 Q4	$822K	Sell	57,626 -265	-0.5%	-$3.76K	﹤0.01%	2374
2023 Q3	$896K	Buy	57,891 +575	+1%	+$8.9K	﹤0.01%	2271
2023 Q2	$900K	Buy	+57,316	New	+$939K	﹤0.01%	2351
2021 Q1	–	Sell	-15,036	Closed	-$274K	–	3027
2020 Q4	$274K	Buy	15,036 +3,770	+33%	+$66.1K	﹤0.01%	2705
2020 Q3	$201K	Buy	+11,266	New	+$205K	﹤0.01%	2687

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

RhumbLine Advisers's TAK Position: Q2 2026 in Review

RhumbLine Advisers reduced its Takeda Pharmaceutical (TAK) stake by 0.19% in Q2 2026, selling an estimated $3.89K and leaving 121,426 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1950.

RhumbLine Advisers first reported a position in TAK in Q3 2020 and has held it in 15 quarters since. The position peaked at $2.25M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

RhumbLine Advisers held 121,426 shares of Takeda Pharmaceutical worth $1.95M as of Q2 2026.
RhumbLine Advisers sold 235 Takeda Pharmaceutical shares in Q2 2026, an estimated $3.89K.
Takeda Pharmaceutical made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1950 holding.
RhumbLine Advisers first reported a position in Takeda Pharmaceutical in Q3 2020 and has held it in 15 quarters since.
RhumbLine Advisers's Takeda Pharmaceutical position peaked at $2.25M in Q1 2026.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.